The partnership expands an existing agreement between the two companies that began last July and will confer exclusive license for South Korea and other Southeast Asian countries.

C1 vaccine technology is derived from a fungus gene expression platform and shows promise for the development of multivalent vaccines that can be used against COVID-19 variants; it does not require large-scale bioreactor facilities to be manufactured, according to the two firms.

Moderna doses 1st patients in COVID-19 vaccine booster trial
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.

CEPI, VBI to develop COVID-19 vaccine against variants
The Coalition for Epidemic Preparedness Innovations (CEPI) will support the development of enveloped viruslike particle vaccine candidates against SARS-CoV-2...

Moderna addresses SARS-CoV-2 variants, ramps up vaccine production
Moderna is pursuing two strategies against emerging SARS-CoV-2 variants. The company is evaluating booster vaccine doses and is increasing vaccine manufacturing...

GSK, CureVac collaborate on next-gen multivalent mRNA COVID-19 vaccines
Glaxo Smith Kline (GSK) and CureVac have entered into a collaboration to jointly develop next-generation messenger RNA (mRNA) vaccines for COVID-19, with...